Eli Lilly acquires the biotechnology company Calytrix, specialized in drugs for blood cancers, for 1,360 million

Eli Lilly buys the biotechnology Calytrix Bio for 1,360 million to strengthen its commitment to innovative therapies against myeloproliferative neoplasms.

fotonoticia 20261116173020 1920

fotonoticia 20261116173020 1920

Add DEMÓCRATA to Google

Ask FREN

Published

1 minute

Most read

Elecciones 29N · Encuestas

La media de las encuestas

Media a 16 de noviembre de 2026 · 17 institutos

  • PP31,5 %
  • PSOE27,2 %
  • Vox18,9 %
  • Frente Amplio6,4 %
  • ERC2,5 %
01020304050ene 2024jul 2024ene 2025jul 2025ene 2026jul 2026

Media del último estudio de cada instituto en 30 días y su evolución semanal desde el 23J. Partidos con al menos un 2 %.

Todas las encuestas

Elecciones generales del 29 de noviembre · Demócrata

Eli Lilly has communicated the acquisition of Calytrix Bio, a biotechnology company focused on the development of treatments for patients with myeloproliferative neoplasms, a type of blood cancer. The transaction is valued at $1.5 billion (€1.36 billion).

The financial agreement includes an initial payment supplemented with additional payments conditioned on the achievement of certain clinical and regulatory milestones. In the transaction, Centerview Partners acts as exclusive financial advisor to Calytrix, while Goodwin Procter provides legal counsel to the biotechnology company. On the part of Lilly, the law firm Paul, Weiss, Rifkind, Wharton & Garrison serves as legal advisor.

The lead candidate of Calytrix is designed to provide disease-modifying activity, with a safety and comfort profile that facilitates early intervention and prolonged treatment over time.

The pharmacological treatments currently available for certain hematological conditions are aimed above all at managing symptoms and complications, leaving room for precision therapies specifically directed at the mutations that cause the disease.

Calytrix was incorporated in 2025, driven by JPMorgan Life Sciences Private Capital, the venture capital arm specialized in life sciences of JPMorgan Asset Management. The company began its journey with a Series A funding round co-chaired by JP Morgan Life Sciences Private Capital and Westlake BioPartners, followed by a Series B round led by Avoro Ventures.

"Calytrix was founded with the conviction that patients with myeloproliferative neoplasms deserve therapies that go beyond the mere control of symptoms," Calytrix Bio’s president and chief executive officer Brad Prosek has said.

"This transaction represents an important step toward accelerating that vision. We expect Lilly to advance the program through clinical trials and explore its potential to benefit patients across the spectrum of the disease. I am deeply grateful to our team, scientific advisors, and committed investors, who have supported the development of the Calytrix program up to its launch in the clinical setting," he added.